8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

被引：248
|
作者：
Eckhardt, Matthias [1 ]
Langkop, Elke [1 ]
Mark, Michael [2 ]
Tadayyon, Mob [2 ]
Thomas, Leo [2 ]
Nar, Herbert [3 ]
Pfrengle, Waldemar [4 ]
Guth, Brian [5 ]
Lotz, Ralf [5 ]
Sieger, Peter [5 ]
Fuchs, Holger [6 ]
Himmelsbach, Frank [1 ]
机构：
[1] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Chem Res, D-88400 Biberach, Germany
[2] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Metab Dis Res, D-88400 Biberach, Germany
[3] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Lead Discovery, D-88400 Biberach, Germany
[4] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Chem Dev, D-88400 Biberach, Germany
[5] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Drug Discovery Support, D-88400 Biberach, Germany
[6] Boehringer Ingelheim Pharm GmbH & Co KG, Dept Drug Metab & Pharmacokinect, D-88400 Biberach, Germany
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2007年 / 50卷 / 26期
关键词：
D O I：
10.1021/jm701280z
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have led to 1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species. 1 is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.
引用
收藏
页码：6450 / 6453
页数：4
相关论文
共 50 条
  • [1] Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
    Thomas, Leo
    Tadayyon, Moh
    Mark, Michael
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (02): : 556 - 563
  • [2] (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
    Thomas, Leo
    Eckhardt, Matthias
    Langkopf, Elke
    Tadayyon, Moh
    Himmelsbach, Frank
    Mark, Michael
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (01): : 175 - 182
  • [3] Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors
    Mo, Di-Wei
    Dong, Shuai
    Sun, Haiyan
    Chen, Jia-Sheng
    Pang, Jian-Xin
    Xi, Bao-Min
    Chen, Wen-Hua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (09) : 1872 - 1875
  • [4] Crystal structure of (R)-2-((6-(3-(1-(2-cyanobenzyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)aminopiperidin-1-yl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl)benzonitrile, C31H30N8O4
    Laus, Gerhard
    Wurst, Klaus
    Nerdinger, Sven
    Schottenberger, Herwig
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES, 2010, 225 (04): : 756 - 758
  • [5] Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Yoshida, Tomohiro
    Akahoshi, Fumihiko
    Sakashita, Hiroshi
    Kitajima, Hiroshi
    Nakamura, Mitsuharu
    Sonda, Shuji
    Takeuchi, Masahiro
    Tanaka, Yoshihito
    Ueda, Naoko
    Sekiguchi, Sumie
    Ishige, Takayuki
    Shima, Kyoko
    Nabeno, Mika
    Abe, Yuji
    Anabuki, Jun
    Soejima, Aki
    Yoshida, Kumiko
    Takashina, Yoko
    Ishii, Shinichi
    Kiuchi, Satoko
    Fukuda, Sayaka
    Tsutsumiuchi, Reiko
    Kosaka, Keigo
    Murozono, Takahiro
    Nakamaru, Yoshinobu
    Utsumi, Hiroyuki
    Masutomi, Naoya
    Kishida, Hiroyuki
    Miyaguchi, Ikuko
    Hayashi, Yoshiharu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (19) : 5705 - 5719
  • [6] Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies
    Wang, Hui-Ling
    Andrews, Kristin L.
    Booker, Shon K.
    Canon, Jude
    Cee, Victor J.
    Chavez, Frank, Jr.
    Chen, Yuping
    Eastwood, Heather
    Guerrero, Nadia
    Herberich, Brad
    Hickman, Dean
    Lanman, Brian A.
    Laszlo, Jimmy, III
    Lee, Matthew R.
    Lipford, J. Russell
    Mattson, Bethany
    Mohr, Christopher
    Yen Nguyen
    Norman, Mark H.
    Pettus, Liping H.
    Powers, David
    Reed, Anthony B.
    Rex, Karen
    Sastri, Christine
    Tamayo, Nuria
    Wang, Paul
    Winston, Jeffrey T.
    Wu, Bin
    Wu, Qiong
    Wu, Tian
    Wurz, Ryan P.
    Xu, Yang
    Zhou, Yihong
    Tasker, Andrew S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (03) : 1523 - 1540
  • [7] Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533)
    Choi, Hojin
    Lee, Jaekwang
    Kim, Young Hoon
    Im, Dai Sig
    Hwang, In-Chang
    Kim, Soo Jin
    Moon, Seung Kee
    Lee, Hong Woo
    Lee, Sung Sook
    Ahn, Soon Kil
    Kim, Sang Woong
    Choi, Nam Song
    Lee, Kyung Joo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (01) : 383 - 386
  • [8] Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
    Su, Qibin
    Banks, Erica
    Bebernitz, Geraldine
    Bell, Kirsten
    Borenstein, Cassandra F.
    Chen, Huawei
    Chuaqui, Claudio E.
    Deng, Nanhua
    Ferguson, Andrew D.
    Kawatkar, Sameer
    Grimster, Neil P.
    Ruston, Linette
    Lyne, Paul D.
    Read, Jon A.
    Peng, Xianyou
    Pei, Xiaohui
    Fawell, Stephen
    Tang, Zhanlei
    Throner, Scott
    Vasbinder, Melissa M.
    Wang, Haoyu
    Winter-Holt, Jon
    Woessner, Richard
    Wu, Allan
    Yang, Wenzhan
    Zinda, Michael
    Kettle, Jason G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (09) : 4517 - 4527
  • [9] Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor
    Chough, Chieyeon
    Joung, Misuk
    Lee, Sunmin
    Lee, Jaemin
    Kim, Jong Hoon
    Kim, B. Moon
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (08) : 1495 - 1510
  • [10] (1R*, 5R*, 7R*, 8S*)-3-(3,4-dihydroxybenzoyl)-4-hydroxy-8-methyl-1,5,7-tris(3-methyl-2-butenyl)-8-(4-methyl-3-pentenyl)bicyclo[3.3.1]non-3-ene-2,9-dione
    Lenta, Bruno Ndjakou
    Noungoue, Diderot Tchamo
    Devkota, Krishna Prasad
    Fokou, Patrice Aime
    Ngouela, Silvere
    Etienne, Tsamo
    Sewald, Norbert
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2007, 63 : o1282 - o1284
12345